Blood levels alone cannot confirm safe testosterone dosing. Asking about androgenic effects and allowing months for response are central to care.
|Videos|April 7, 2021
LARC in the time of COVID-19 and telehealth: Part 2
This video interview features Rachael Phelps, MD, Medical Director at Planned Parenthood of Central and Western New York, and of the Rochester LARC Initiative; and Amber Truehart, MD, Assistant Professor of Obstetrics and Gynecology, Section of Family Planning and Contraceptive Research at the University of Chicago.
Advertisement
Advertisement
Related to this article
A global consensus defines what the evidence supports for testosterone in women. Benefits for strength, mood, and cognition lack randomized data.
A testosterone patch improved sexual desire in trials but never won US approval. Normal female physiology defines what replacement should target.
The WHI never studied testosterone, yet it chilled conversations about every hormone, with lasting consequences for women’s sexual health.
As estrogen came to define menopause care, testosterone faded from view, and the oral combination clinicians relied on was never FDA approved.
Androgen therapy for women predates the headlines by decades. Early research showed promise for desire, but long-term safety data never caught up.
Mental health, bias, and trauma shape sexual health visits, and histories should assess function, not just risk, according to Sameena Rahman, MD.
Samples from a large UK screening trial supported validation of the investigational Evident ovarian cancer test, according to Dawn Mattoon, PhD.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
What biomarker-guided preeclampsia care could look like
2
Testosterone for women: Global consensus and physiologic dosing
3
Testosterone physiology in women and the long road to approval
4
Testosterone in women: Androgenic adverse events and lab monitoring
5